CClinicalTrials.gg
RecruitingNCT04793581Updated Jul 30, 2024

Assessment of the Utility of the Pantheris Small Vessel (SV) System

An interventional study of Atherectomy in Peripheral Arterial Disease, sponsored by Avinger, Inc.. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-30.

Sponsored by Avinger, Inc. · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

A single-arm study to assess the utility of the Pantheris SV catheter in addressing peripheral artery disease in arteries located below the knee. Data will be collected on the percent stenosis pre- and post-atherectomy and then symptoms and adverse events noted at 30 days, 6 months, and 1 year after the procedure.

Read the detailed description

This is a post-market, single-arm study of the optical coherence tomography (OCT)-guided directional atherectomy catheter, Pantheris SV. Patients presenting with reduced blood flow in the lower extremity arteries will under directional atherectomy, followed by adjunctive therapy as deemed necessary by the physician, and then adverse events and symptom resolution will be documented at 30 days, 6 months, and 1 year after the procedure. Primary safety endpoints are related to adverse events and will be assessed at the time of the procedure and at 30 days after the procedure. Effectiveness endpoints center on restoration of blood flow.

02

Conditions studied

  • Peripheral Arterial Disease

Keywords

  • peripheral artery disease (PAD) below-the-knee atherectomy
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • 18 years or older
  • Target lesion in the infragenicular segment
  • At least 1 pedal vessel noted in the foot
  • Rutherford classification 3 to 6
  • Willing to give informed consent

Exclusion criteria

Exclusion Criteria:

  • if female, is pregnant or breast feeding
  • has had surgery or endovascular procedure within 30 days prior to the index procedure
  • has planned surgery within 30 days after the index procedure
  • had a major bleeding event within 60 days prior to the index procedure
  • currently in the treatment phase of a drug or device trial
  • has anticipated life span of less than 1.5 years
  • is unwilling to present to the investigator at 30 days, 6 moths, or 1 year after the index procedure
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Other
    Single Arm

    Single-arm study

    Device: Atherectomy

Interventions

  • DeviceAtherectomy

    Directional atherectomy of lesions below the knee.

05

What researchers measure

Primary outcomes

  1. Major Adverse Events

    freedom from cardiovascular-related events

    Time frame: from procedure to 30 days post-procedure

  2. Technical success

    defined as residual stenosis \< 50 percent after atherectomy

    Time frame: At 1 day post-procedure

Secondary outcomes

  1. Procedure success

    defined as residual stenosis \< 30 percent post adjunctive therapy

    Time frame: At 1 day post-procedure

  2. Freedom from target vessel revascularization (TVR)

    revascularization needed further

    Time frame: At 6 and 12 months post-procedure

  3. Primary patency

    change in peak systolic velocity ratio (PSVR)

    Time frame: At 6 and 12 months post-procedure

  4. Ankle-Brachial Index (ABI)

    change since index procedure

    Time frame: At 6 and 12 months post-procedure

  5. Rutherford Classificaiton

    Change since index procedure

    Time frame: At 30 days, 6 months, and 1 year post-procedure

06

Study locations

2 of 2 sites recruiting
  • Advanced Cardiac and Vascular Centers
    Grand Rapids, Michigan 49525, United States
    • Abby Mize, BS · Contact · amize@acvcenters.com · 616-447-8220
    • Jihad Mustapha, MD · Principal investigator
    Recruiting
  • Eastlake Cardiovascular PC
    Saint Clair Shores, Michigan 48080, United States
    • Rewaa Yas, MS · Contact · ryas@eastlakecv.com · 586-944-2800
    • Thomas Davis, MD · Principal investigator
    Recruiting
07

References and documents

Publications

  • Khalili H, Jeon-Slaughter H, Armstrong EJ, Baskar A, Tejani I, Shammas NW, Prasad A, Abu-Fadel M, Brilakis ES, Banerjee S. Atherectomy in below-the-knee endovascular interventions: One-year outcomes from the XLPAD registry. Catheter Cardiovasc Interv. 2019 Feb 15;93(3):488-493. doi: 10.1002/ccd.27897. Epub 2018 Nov 30. PubMed 30499198 ↗
  • Schwindt AG, Bennett JG Jr, Crowder WH, Dohad S, Janzer SF, George JC, Tedder B, Davis TP, Cawich IM, Gammon RS, Muck PE, Pigott JP, Dishmon DA, Lopez LA, Golzar JA, Chamberlin JR, Moulton MJ, Zakir RM, Kaki AK, Fishbein GJ, McDaniel HB, Hezi-Yamit A, Simpson JB, Desai A. Lower Extremity Revascularization Using Optical Coherence Tomography-Guided Directional Atherectomy: Final Results of the EValuatIon of the PantheriS OptIcal COherence Tomography ImagiNg Atherectomy System for Use in the Peripheral Vasculature (VISION) Study. J Endovasc Ther. 2017 Jun;24(3):355-366. doi: 10.1177/1526602817701720. Epub 2017 Apr 10. PubMed 28393673 ↗

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT04793581
Lead sponsor
Avinger, Inc.
Responsible party
Sponsor
First posted
Mar 11, 2021
Start date
Jan 29, 2021
Primary completion
Feb 1, 2025 (estimated)
Completion
Aug 1, 2025 (estimated)
Last update
Jul 30, 2024

Study contacts

Thomas Lawson, PhD
Contact
tlawson@avinger.com
6502417030
Ruth Lira, BS
Contact
rlira@avinger.com
6502417031
Jaafer Golzar, MD
study chair · Avinger, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion